Ustekinumab biosimilar for treating inflammatory conditions

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has recommended ustekinumab biosimilar (Steqeyma) 45 mg/0.5 mL pre-filled syringe, 90 mg/1 mL pre-filled syringe, and 130 mg/26 mL vial for listing on the MOH Standard Drug List (SDL). The decision was based on the acceptable pricing proposal from the company.

Funding status

SDL subsidy will apply from 1 April 2026 to all registered indications of ustekinumab biosimilar (Steqeyma) 45 mg/0.5 mL pre-filled syringe, 90 mg/1 mL pre-filled syringe, and 130 mg/26 mL vial in Singapore.

SDL subsidy does not apply to other brand(s), formulation(s) or strength(s) of ustekinumab

Guidance_Ustekinumab biosimilar for treating inflammatory conditions (6 February 2026)